| Drug Class | Company | Drug Name | Alt Name | Drug Status | Notes | AIDS# |
| Bactericidal-ATP Synthase Inhibitor | Johnson & Johnson | Bedaquiline | TMC-207; R207910 | Phase III | Not Yet Recruiting |
222088
|
| Cell Wall Synthesis Inhibitor | Sequella | SQ-109 | | Phase II | Ongoing, Not Recruiting |
207396
|
| DNA Replication Inhibitor/TB Cell division inhibitor | Parke-Davis; Kyorin Pharm; Pfizer | Tequin™ | Gatifloxacin; GTFX; BMS-206584; AM-1155; CG 5501; PD-135432; GAT | Phase III | Recruitment Unknown |
044913
|
| DNA Replication Inhibitor/TB Cell division inhibitor | Bayer | Flagyl™ | Metronidazole; Bayer 5360; Methronidazole; MTZ; RP 8823; SC 10295; Wagitran | Phase II | Ongoing, Not Recruiting |
007953
|
| DNA Replication Inhibitor/TB Cell division inhibitor | Daiichi Pharm; Sanofi-Aventis; Ortho-Mcneil | Levofloxacin | S-(-)-Ofloxacin; DR-3355; RWJ-25213; Cravit; L-Ofloxacin; LVX; Levaquin; Tavanic | Phase III | Completed |
002307
|
| DNA Replication Inhibitor/TB Cell division inhibitor | Bayer; Schering-Plough | Moxifloxacin | MXFX; BAY 12-8039 | Phase III | Ongoing, Not Recruiting |
070017
|
| Intracellular NO Release | Pathogenesis Corp; Chiron | PA-824 | | Phase II | Recruiting |
007331
|
| Mycolic acid biosynthesis inhibitor | Otsuka Pharm | Delamanid | OPC-67683 | Phase III | Recruiting |
182259
|
| Protein Synthesis Inhibitor/TB grwoth Inhibitor | Pharmacia & Upjohn, Inc.; Pfizer | Sutezolid | PNU-100480; PF-02341272 | Phase II | Completed |
045415
|
| Protein Synthesis Inhibitor/TB grwoth Inhibitor | Astrazeneca | AZD-5847 | | Phase II | Not Yet Recruiting |
|
| Protein Synthesis Inhibitor/TB grwoth Inhibitors | Pharmacia & Upjohn, Inc.; Pfizer | Zyvox™ | Linezolid; PNU-100766 | Phase II | Ongoing, Not Recruiting |
070944
|
| TB Cell division inhibitor | Marion Merrel Dow; Sanofi-Aventis | Priftin™ | Rifapentine; MDL 473; RPE; RPT; Cyclopentyl rifampin; DL 473; R 77-3 | Phase III | Ongoing, Not Recruiting |
007686
|